Caitlin Clark seen carrying a baby at Indiana Fever game amid injury absence
Print Close
By Jackson Thompson
Published May 29, 2025
Caitlin Clark may be offering her babysitting services while unable to provide her basketball ones.
Clark was seen carrying a toddler around CFG Bank Arena in Baltimore on Wednesday night. Clark was not active for the Indiana Fever's game against the Washington Mystics, as she sat out with a quad injury.
Footage of Clark carrying the child was posted to social media by Yahoo Sports.
CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM
Sports Illustrated reported that the child is the son of Indiana assistant coaches Karima Christmas-Kelly and Austin Kelly.
Clark's Fever went on to lose to the Mystics in her absence.
The team announced on Monday that Clark will miss at least two weeks with the quad issue. However, Fever head coach Stephanie White said there is a silver lining to Clark not being able to play.
SPARKS' KELSEY PLUM DELIVERS TAUNT AFTER BLOWING BY SKY'S ANGEL REESE ON LAY UP
"I think it's a great opportunity for Caitlin to watch the game from the sideline, to grow in a coaching kind of mindset and see some different things that we might be talking about on film, addressing in practice, to see it develop in live action," White said, via CBS Sports .
"As players you see [the game] in a micro viewpoint, and when you're on the sideline, and you're watching it as a whole, you get to see it a different way from a macro viewpoint. I think it's gonna give her a unique perspective, and she's gonna come back better, and it's gonna help us be better.
CLICK HERE TO GET THE FOX NEWS APP
"It is great to grow when you're on the floor, but you also see the game at different levels when you're not on the floor," White added. "You see it at one level or two levels when you're on the floor, and you often [equate] it to being in a coach's mindset, being in a coach's viewpoint. Listening to us and our conversations, whether it's in practice or on the sidelines, talking about what our emphasis is, what we're looking for, and you see it from a different perspective."
Clark will be out for the team's upcoming games against the Connecticut Sun and Chicago Sky. The earliest Clark would return is June 10 on the road against the Atlanta Dream.
Follow Fox News Digital's sports coverage on X , and subscribe to the Fox News Sports Huddle newsletter . Print Close
URL
https://www.foxnews.com/sports/caitlin-clark-seen-carrying-baby-indiana-fever-game-amid-injury-absence
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
"Superstars at 25 don't get traded"- Draymond Green recalls getting confused between Doncic trade and Warriors landing Kevin Durant
"Superstars at 25 don't get traded"- Draymond Green recalls getting confused between Doncic trade and Warriors landing Kevin Durant originally appeared on Basketball Network. The Luka Doncic trade will certainly be a topic of discussion for years to come. A decision that shocked the entire NBA ecosystem, with the Dallas Mavericks shipping the Slovenian talent to the Los Angeles Lakers after a great seven-year association. Advertisement Such was the magnitude of the trade that transpired on February 2nd, 2025, and everyone had a story to tell. However, Draymond Green's reaction was certainly a little amusing as the four-time champion narrated his episode on "Jimmy Kimmel Live." Recounting the night of the trade announcement, Draymond revealed he was at a Warriors charity poker tournament. Ten minutes before the news broke out, the 2016 DPOY recalled talking with owner Joe Lacob, who told him about almost having Kevin Durant in the Bay Area. "So we're at this tournament and I go sit down and about 15 minutes later, Steph yells, 'Draymond did you see the trade.' I go, 'It happened?' Steph goes, 'Wait, who?' and I said, 'Oh never mind, Nobody,"' revealed Draymond, who assumed Lacob had pulled off the Durant trade with the Phoenix Suns. Nonetheless, learning about Luka's trade, the defensive savant said the following. Advertisement "I couldn't believe it. Superstars at 25 don't get traded. Luka is a megastar. Just coming off the NBA Finals. You just don't see that in the NBA. I immediately wondered when I had to be next, it's coming for me soon," Dray told host Jimmy. The Warriors star was coming off a second round exit against the Timberwolves but had managed to make the 2025 NBA All-Defensive First Team. Pursuing "The Slim Reaper" Looking back to the 2024-25 trade deadline, the Warriors were keen on reuniting with Durant. During his three-year stint in the Bay Area, the 6'11" forward helped the franchise secure two championship banners, earning Finals MVP honors both times. Hence, GSW's front office was trying to work out the best deal with the Suns. But, before things could be finalized, Durant had categorically disagreed with a homecoming in the Bay. The fifteen-time All-Star was done with his fair share of scrutiny. As the deadline appeared closer, GM Mike Dunleavy Jr. and management found themselves in a lurch. Ultimately, they decided to go ahead with Jimmy Butler's gamble, which turned out to be a beneficial move for the most part. Advertisement Related: Luc Longley on why he and Michael Jordan couldn't get along: "Mike was doing what he did to rookies, what he was doing to me" Blockbuster trade on the cards for the Warriors? With free agency not far away, there has been a lot of chatter around the Dubs making a strong push for a star player. Since winning their 2022 championship, Coach Steve Kerr and his crew have not had the desired success for various reasons. Blessed to have a generational talent in Curry, the management cannot afford to let go of his championship window. Entering his 17th season, the two-time MVP has shown no signs of slowing down. Hence, given his invaluable contributions to the franchise and the city of San Francisco, the front office owes him a shot at his fifth title. Not to forget his legacy, known as the face that changed the game. Advertisement Related: "What is this? Some Brazilian fake news?" - Goran Dragic revealed his initial reaction to the Luka Doncic trade This story was originally reported by Basketball Network on Jun 7, 2025, where it first appeared.
Yahoo
27 minutes ago
- Yahoo
Why Kruk believes Giants ‘redefined' themselves after Padres series
Why Kruk believes Giants 'redefined' themselves after Padres series originally appeared on NBC Sports Bay Area NBC Sports Bay Area's Mike Krukow explained how the Giants 'redefined' themselves with a pair of comeback wins over the San Diego Padres amid recent roster moves in talking to KNBR's 'Murph and Markus' on Friday. Advertisement 'You're into June, and now you're in arguably the biggest series of the year for you so far, given how they lost the first four games to the Padres, and they needed to prove to themselves that they can hang with the Padres; with that move going down, that's exactly what they did,' Krukow told Brian Murphy and Markus Boucher. 'They salvaged the series and redefined themselves. 'I'm repeating myself, but it is the most important thing I've said today in regards to the Giants. What has come out of this series is that they have redefined themselves as a team; they see themselves as a better team because of what they did those last two games of the four-game series.' San Francisco took the last two games of its dramatically narrow four-game series with San Diego after dropping the first two. As Krukow said, the Giants needed to leave with something after dropping their first four games against the Padres earlier in the 2025 MLB season. And, after splitting the series in which every game was decided by one run, the Giants appear rejuvenated to many, including Krukow, and with much thanks to the franchise's first-year president of baseball operations. Advertisement 'With Buster [Posey] making the move, that had everything to do with it,' he said. The former San Francisco pitcher highlighted Posey's decision to shake up the roster, specifically by designating fan favorite LaMonte Wade Jr. for assignment, as the gutsy decision-making that the organization desperately needed. Krukow felt the Giants needed a spark to get back on track and prove their seriousness. 'Oh, 100 percent,' Krukow said about Posey's leadership being on display. 'And it's instinct, too; instinct to know that everyone in that clubhouse is waiting – waiting for a game-changing move. What this also says is – who's a better guy than LaMonte Wade Jr.? Nobody. And he's a fan favorite. Advertisement 'That was not an easy decision, as you kept thinking he was going to put it together, and he couldn't do it, and time ran out.' After making some changes and grinding out a pair of wins over San Diego, San Francisco appears to have 'redefined' itself, according to Krukow. The 35-28 Giants, who now trail the 35-26 Padres by one game for the National League's second wildcard spot, will take it. Download and follow the Giants Talk Podcast
Health Line
33 minutes ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
